Drug Trial Radar · NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Nov 22, 2022
Primary completion
Apr 19, 2027
Study completion Nov 15, 2030
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Conditions
- Relapsed or Refractory Multiple Myeloma
- Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions
JNJ-79635322Drug
JNJ-79635322 will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Up to 2 years 5 months
- Parts 1 and 2: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 2 years 5 months
- Part 2: Number of Participants with Abnormalities in Laboratory ValuesTime frame: Up to 2 Years 5 months
Locations
29 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Icahn School of Medicine at Mt. Sinai
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
UZ Antwerpen
Edegem, Belgium · Recruiting
UZ Gent
Ghent, Belgium · Recruiting
CHU de Liege
Liège, Belgium · Recruiting
CHU Nantes
Nantes, France · Recruiting
CHU Lyon Sud
Pierre-Bénite, France · Recruiting
Chu Rennes Hopital Pontchaillou
Rennes, France · Completed
Institut Claudius Regaud
Toulouse, France · Recruiting
Japanese Red Cross Medical Center
Shibuya City, Japan · Active not recruiting
Osaka University Hospital
Suita-shi, Japan · Active not recruiting
The Cancer Institute Hospital of JFCR
Tokyo, Japan · Completed
VUMC Amsterdam
Amsterdam, Netherlands · Recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Recruiting
UMC Utrecht
Utrecht, Netherlands · Recruiting
Hosp. Univ. Germans Trias I Pujol
Badalona, Spain · Recruiting
Hosp Clinic de Barcelona
Barcelona, Spain · Recruiting
Hosp Univ Fund Jimenez Diaz
Madrid, Spain · Recruiting
Clinica Univ. de Navarra
Pamplona, Spain · Recruiting
Hosp Clinico Univ de Salamanca
Salamanca, Spain · Recruiting
University College Hospital
London, United Kingdom · Recruiting
Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.